{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:48:53Z","timestamp":1791650933131,"version":"4.3.4"},"reference-count":43,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,10,11]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>To date, evidence on late-onset immune-related adverse events (irAEs) with immune checkpoint inhibitors (ICIs) is limited to a small number of clinical cases. This study aimed to identify drug- and patient-related characteristics potentially associated with the reporting of late-onset irAEs with ICIs in VigiBase, the WHO global database of individual case safety reports (ICSRs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Observational study comparing deduplicated ICSRs with ICIs reporting late-onset irAEs (occurred &gt;90\u2009days after ICI discontinuation) versus ICSRs with ICIs not reporting late-onset irAEs, collected in VigiBase from 2011 to December 31, 2022. Logistic regression was used to model the relationship between drug-related and patient-related characteristics of ICSRs and the reporting of late-onset irAEs. Significance was determined for variables with the lower bound of the 95% CI of the reporting OR (ROR) higher than 1 and a p value &lt;0.05.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study population consisted of 6006 ICSRs with ICI-related irAEs (4574, 76.2%, originated from Europe; 3900, 64.9%, involved males; median patient age was 67 years, IQR 59\u201374 years). Of these, 344 (5.7%) ICSRs reported a total of 388 late-onset irAEs, among which the most frequent were thyroiditis (n=45), pneumonitis (n=37), interstitial lung disease (n=25), hepatitis (n=23) and vitiligo (n=19). Median time to onset since ICI discontinuation was 167 days (IQR 115\u2013294\u2009days), with negligible proportion (3.2%) of co-reported antineoplastic agents during the discontinuation period. Logistic regression models showed disproportionate reporting of late-onset irAEs with ICI combination therapy (ROR 2.33, 95% CI 1.19 to 4.57), reporting of multiple irAEs (ROR 3.96, 95% CI 2.85 to 5.52), reporting of cutaneous irAEs (ROR 1.83, 95% CI 1.24 to 2.71), and melanoma (ROR 1.47, 95% CI 1.04 to 2.06).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This global pharmacovigilance study provides the largest case series of late-onset irAEs with ICIs to date and identifies characteristics of ICSRs associated with disproportionate reporting. Dedicated prospective observational studies focused on long-term sequelae, quality of life and survival of patients developing late-onset irAEs with ICIs should be planned to confirm whether these reporting characteristics are predictors of actual occurrence. Furthermore, translational research should be encouraged to clarify the molecular mechanisms underlying late-onset irAE development.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2024-009902","type":"journal-article","created":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T20:55:14Z","timestamp":1730667314000},"page":"e009902","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4946-7926","authenticated-orcid":false,"given":"Roberta","family":"Noseda","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bedussi","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Giunchi","sequence":"additional","affiliation":[{"name":"Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Fusaroli","sequence":"additional","affiliation":[{"name":"Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0487-7996","authenticated-orcid":false,"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[{"name":"Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Ceschi","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland"},{"name":"Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera italiana, Lugano, Switzerland"},{"name":"Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland"},{"name":"Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,11,3]]},"reference":[{"key":"2025100309233481000_12.11.e009902.1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","article-title":"Trends in the approval of cancer therapies by the FDA in the twenty-first century","volume":"22","author":"Scott","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2025100309233481000_12.11.e009902.2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1470-2045(23)00575-2","article-title":"Adjuvant or neoadjuvant treatment with immune checkpoint inhibitors: re-assessing the risk-benefit ratio","volume":"25","author":"Delyon","year":"2024","journal-title":"Lancet Oncol"},{"key":"2025100309233481000_12.11.e009902.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2025100309233481000_12.11.e009902.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102590"},{"key":"2025100309233481000_12.11.e009902.5","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-022-01395-7"},{"key":"2025100309233481000_12.11.e009902.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0"},{"key":"2025100309233481000_12.11.e009902.7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025100309233481000_12.11.e009902.8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s43018-024-00730-3","article-title":"Clinical and translational attributes of immune-related adverse events","volume":"5","author":"Suijkerbuijk","year":"2024","journal-title":"Nat Cancer"},{"key":"2025100309233481000_12.11.e009902.9","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100309233481000_12.11.e009902.10","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma","volume":"32","author":"Owen","year":"2021","journal-title":"Ann Oncol"},{"key":"2025100309233481000_12.11.e009902.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30494-0"},{"key":"2025100309233481000_12.11.e009902.12","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/j.jtho.2019.11.015","article-title":"PD-1 Blockers: Staying Long in the Body and Delayed Toxicity Risks","volume":"15","author":"Fukudo","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2025100309233481000_12.11.e009902.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609"},{"key":"2025100309233481000_12.11.e009902.14","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025100309233481000_12.11.e009902.15","first-page":"1067","article-title":"Late-onset toxicities of monoclonal antibodies in cancer patients","volume":"14","author":"Alalawi","year":"2022","journal-title":"Immunotherapy (Los Angel)"},{"key":"2025100309233481000_12.11.e009902.16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2021.03.010","article-title":"Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy","volume":"149","author":"Ghisoni","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025100309233481000_12.11.e009902.17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejca.2018.02.019","article-title":"Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient","volume":"95","author":"Mandal\u00e0","year":"2018","journal-title":"Eur J Cancer"},{"key":"2025100309233481000_12.11.e009902.18","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0531"},{"key":"2025100309233481000_12.11.e009902.19","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","article-title":"Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance","volume":"15","author":"Raschi","year":"2020","journal-title":"Target Oncol"},{"key":"2025100309233481000_12.11.e009902.20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113480","article-title":"Pre-Existing Cardiovascular Conditions as Clinical Predictors of Myocarditis Reporting with Immune Checkpoint Inhibitors: A VigiBase Study","volume":"12","author":"Noseda","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025100309233481000_12.11.e009902.21","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1007\/s43441-020-00130-6","article-title":"WHODrug: A Global, Validated and Updated Dictionary for Medicinal Information","volume":"54","author":"Lagerlund","year":"2020","journal-title":"Ther Innov Regul Sci"},{"key":"2025100309233481000_12.11.e009902.22","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"2025100309233481000_12.11.e009902.23","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"2025100309233481000_12.11.e009902.24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007675","article-title":"Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy","volume":"12","author":"Chen","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2025100309233481000_12.11.e009902.25","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40264-023-01320-5","article-title":"Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians","volume":"46","author":"Raschi","year":"2023","journal-title":"Drug Saf"},{"key":"2025100309233481000_12.11.e009902.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037"},{"key":"2025100309233481000_12.11.e009902.27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030571"},{"key":"2025100309233481000_12.11.e009902.28","doi-asserted-by":"crossref","unstructured":"Moslehi JJ , Salem J-E , Sosman JA , et al . Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 2018;391. doi:10.1016\/S0140-6736(18)30533-6","DOI":"10.1016\/S0140-6736(18)30533-6"},{"key":"2025100309233481000_12.11.e009902.29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000261","article-title":"Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors","volume":"8","author":"Dolladille","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100309233481000_12.11.e009902.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214"},{"key":"2025100309233481000_12.11.e009902.31","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920937612","article-title":"Efficacy of PD-1\/PD-L1 blockade monotherapy in clinical trials","volume":"12","author":"Zhao","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"2025100309233481000_12.11.e009902.32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030738","article-title":"Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025100309233481000_12.11.e009902.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"2025100309233481000_12.11.e009902.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611299"},{"key":"2025100309233481000_12.11.e009902.35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6750"},{"key":"2025100309233481000_12.11.e009902.36","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286"},{"key":"2025100309233481000_12.11.e009902.37","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3390\/curroncol31010028","article-title":"Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use","volume":"31","author":"Li","year":"2024","journal-title":"Curr Oncol"},{"key":"2025100309233481000_12.11.e009902.38","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0336-3"},{"key":"2025100309233481000_12.11.e009902.39","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"E Clin Med"},{"key":"2025100309233481000_12.11.e009902.40","doi-asserted-by":"crossref","unstructured":"Fusaroli M , Mitchell J , Rudolph A , et al . Causal inference tools for pharmacovigilance: using causal graphs to systematize biases, plan disproportionality analyses, and reduce the risk of spin. OSF Preprints 2024. doi:10.31219\/osf.io\/h5w9u","DOI":"10.31219\/osf.io\/h5w9u"},{"key":"2025100309233481000_12.11.e009902.41","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.therap.2020.02.022","article-title":"Uses of pharmacovigilance databases: An overview","volume":"75","author":"Bihan","year":"2020","journal-title":"Therapie"},{"key":"2025100309233481000_12.11.e009902.42","doi-asserted-by":"publisher","DOI":"10.1177\/009286150804200501"},{"key":"2025100309233481000_12.11.e009902.43","doi-asserted-by":"crossref","first-page":"113505","DOI":"10.1016\/j.ejca.2023.113505","article-title":"The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects","volume":"199","author":"Ertl","year":"2024","journal-title":"Eur J Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:23:46Z","timestamp":1759508626000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":43,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,3]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/jitc-2024-009902"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009902","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}